SciSparc Ltd.
Announces Initial Positive Results for
the Cocaine Addiction Treatment of Clearmind Medicine
Inc.
SciSparc
and Clearmind recently announced the filing of a patent application
related to treating cocaine addiction
TEL AVIV, Israel, June 7,
2022 -- InvestorsHub NewsWire -- SciSparc Ltd. (NASDAQ:
SPRC), a specialty clinical-stage
pharmaceutical company focusing on the development of therapies to
treat disorders of the central nervous system (the "Company" or
"SciSparc"), today announced that initial positive pre-clinical
results for treatment for cocaine addiction using MEAI, a novel
psychedelic molecule of Clearmind Medicine Inc. ("Clearmind") (CSE:
CMND), (OTC: CMNDF), (FSE: CWY0).
Pursuant to
SciSparc last announcement on June 2, 2022, whereby the Company
announced the collaborated filing of a provisional patent
application related to treating cocaine addiction with Clearmind
based on SciSparc's CannAmide™ compound and Clearmind's MEAI,
the pre-clinical trials show possible positive results which may
positively affect our collaboration.
"We are excited
about Clearmind's results, in light of the potential synergistic
effect between SciSparc's CannAmide compound and Clearmind's MEAI,
as previously demonstrated in joint studies, which reflected the
dose dependency effect. We plan to continue to investigate these
findings, which for the first time point to a potential treatment
for cocaine addiction. Since commencing the collaboration with
Clearmind, we have been able to present successful results for our
proprietary combination treatment" commented Oz Adler, SciSparc's
Chief Executive Officer. "It is our intention to further
investigate the effect of this treatment on different addictions
and other binge behaviors".
The pre-clinical
trial was led by Professor Gal Yadid and his team from the Gonda
Multidisciplinary Brain Research Center located at Bar Ilan
University (Ramat Gan, Israel) and was designed to
evaluate the possible reward-like
effects of MEAI. Four different doses of MEAI were compared to
cocaine in the conditioned place preference (CPP) model in male
Sprague-Dawley rats. Rats received either MEAI or cocaine. Based on
statistically significant reductions in the reward effect as
compared to cocaine, it was determined that MEAI is not rewarding.
Additionally, some rats that received cocaine were treated with
MEAI on the test day to determine if MEAI has a treatment-like
effect. Rats were conditioned with cocaine and on the day of the
test were treated with MEAI. The results obtained suggest MEAI's
ability to abolish cocaine induced conditioned place preference.
The results of this ground-breaking research show potential for the
first dedicated cocaine addiction treatment.
About
SciSparc Ltd. (NASDAQ:SPRC):
SciSparc Ltd. is a
specialty clinical-stage pharmaceutical company led by an
experienced team of senior executives and scientists. SciSparc's
focus is on creating and enhancing a portfolio of technologies and
assets based on cannabinoid pharmaceuticals. With this focus, the
Company is currently engaged in the following drug development
programs based on THC and/or non-psychoactive cannabidiol (CBD):
SCI-110 for the treatment of Tourette syndrome and for the
treatment of Alzheimer's disease and agitation; SCI-160 for the
treatment of pain; and SCI-210 for the treatment of autism spectrum
disorder and status epilepticus.
About
Clearmind Inc. (CSE: CMND), (OTC: CMNDF), (FSE: CWY0)
Clearmind is a new
biotech company focused on the discovery and development of safe
and novel psychedelic-derived therapeutics to treat alcohol use
disorder and other pressing health challenges.
The
Israeli-Canadian company holds several patents for the
non-hallucinogenic compound MEAI (5-methoxy-2-aminoindane, a novel
psychoactive substance). The company intends to seek additional
patents for its compounds whenever warranted and will remain
opportunistic regarding the acquisition of additional intellectual
property to build its portfolio.
Clearmind has established
a research collaboration with the Hebrew University of Jerusalem
and Bar Ilan University. The partnerships aim to expand its R&D
capabilities and discover new candidate treatments for other mental
health issues.
Forward-Looking
Statements:
This press release
contains forward-looking statements within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and other Federal securities laws. For example, SciSparc is
using forward-looking statements when it discusses the potential
benefits of CannAmide™ and MEAI
for treating cocaine abuse and the intention of SciSparc to further
investigate the effect of CannAmide with MEAI on different
addictions and other binge behaviors. Historic results of
scientific research and clinical and preclinical trials do not
guarantee that the conclusions of future research or trials will
suggest identical or even similar conclusions. Because such
statements deal with future events and are based on SciSparc's
current expectations, they are subject to various risks and
uncertainties and actual results, performance or achievements of
SciSparc could differ materially from those described in or implied
by the statements in this press release. The forward-looking
statements contained or implied in this press release are subject
to other risks and uncertainties, including those discussed under
the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F
filed with the U.S. Securities and Exchange Commission ("SEC")
on April 28, 2022, and in subsequent filings with
the SEC. Except as otherwise required by law, SciSparc disclaims
any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date they were made, whether
as a result of new information, future events or circumstances or
otherwise.
Investor
Contact:
IR@scisparc.com
Tel:
+972-3-6167055